CAMBRIDGE, Mass., April 6, 2015 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE: BMR) announced today the signing of a 295,000 square foot lease at 675 West Kendall by Alnylam Pharmaceuticals in Cambridge, Massachusetts providing Alnylam with Class A laboratory and office space in the heart of Kendall Square.
Alnylam Pharmaceuticals is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers. This growing life science company will occupy all the rentable space available on the six floors of 675 West Kendall when the lease with the current tenant, Vertex Pharmaceuticals, ends in May 2018.
"BioMed Realty has built our business on helping life science companies be successful by providing the laboratory and office platform for companies like Alnylam to conduct breakthrough science that help patients throughout the world," said Bill Kane, Senior Vice President for BioMed Realty. "We will welcome Alnylam to their new home, and provide them our unique real estate expertise to ensure they have the best facility to create life-changing treatments for patients."
Since the beginning of the year, BioMed Realty has signed new leases in Kendall Square and East Cambridge aggregating almost 500,000 square feet, reflecting the demand and vitality of the largest life science urban center in the world.
As a tenant at 675 West Kendall, Alnylam employees will have the benefit of engaging in an amenity-rich, privately owned and operated 10-acre mixed use site that offers top-quality restaurants, kayak and canoe rentals, ice skating, outdoor concerts, and a farmers market.
About BioMed Realty Trust
BioMed Realty, with its trusted expertise and valuable relationships, delivers optimal real estate solutions for biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty owns or has interests in properties comprising approximately 18.0 million rentable square feet. Additional information is available at www.biomedrealty.com. Follow us on Twitter @biomedrealty.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: adverse economic or real estate developments in the life science industry or the company's target markets, including with respect to Cambridge, Massachusetts; and general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate). For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biomed-realty-signs-alnylam-pharmaceuticals-to-295000-square-foot-lease-for-class-a-laboratory-and-office-space-in-cambridge-300061022.html
SOURCE BioMed Realty Trust, Inc.
Jim Cullinan, Vice President, Marketing, (858) 753-8661, email@example.com